加贝酯联合奥曲肽治疗急性轻度胰腺炎临床观察  

Clinical observation of gabexate combined with octreotide in the treatment of patients with acute mild pancreatitis

作　　者：杨俊芳[1] 黄瑞娜[1] YANG Jun-fang;HUANG Rui-na(Department of Gastroenterology,Pingdingshan First People’s Hospital,Pingdingshan 467000,China)

机构地区：[1]平顶山市第一人民医院消化内科,河南平顶山467000

出　　处：《社区医学杂志》2021年第15期935-938,共4页Journal Of Community Medicine

摘　　要：目的探究加贝酯联合奥曲肽治疗轻度急性胰腺炎患者效果及其对肠黏膜屏障功能、血清淀粉酶(Samy)和尿淀粉酶(Uamy)水平的影响。方法选取本院消化科2018-09-10-2020-09-10收治的81例轻度急性胰腺炎患者为研究对象。以随机数字表法分为2组,对照组40例给予静脉持续泵入奥曲肽治疗,观察组41例在对照组基础上联合加贝酯治疗,对比2组患者临床疗效、肠黏膜屏障功能、生化指标和治疗安全性。结果经治疗,对照组总有效率为77.50%,低于观察组的97.56%,χ^(2)=7.530,P=0.006。治疗后,对照组内毒素水平为(4.35±1.28)EU/mL,高于观察组的(3.04±0.96)EU/mL,t=5.219,P<0.001;血浆二胺氧化酶(DAO)水平为(4.16±1.13)ng/L,高于观察组的(2.84±0.55)ng/L,t=6.710,P<0.001;D-乳酸水平为(2.87±0.31)mg/L,高于观察组的(2.04±0.26)mg/L,t=13.069,P<0.001;尿乳果糖/甘露醇(L/M)水平为0.23±0.05,高于观察组的0.13±0.03,t=10.946,P<0.001。治疗后,对照组Samy水平为(451.02±86.70)IU/L,高于观察组的(401.25±71.45)IU/L,t=2.822,P=0.006;Uamy水平为(1674.19±714.23)IU/L,高于观察组的(1141.25±469.24)IU/L,t=3.979,P<0.001。对照组和观察组不良反应发生率分别为12.50%和17.07%,差异无统计学意义,χ^(2)=0.336,P=0.562。结论加贝酯联合奥曲肽应用于轻度急性胰腺炎患者,可通过恢复肠黏膜屏障功能调节Samy和Uamy水平,改善患者临床症状,提高临床疗效,且安全性较高。Objective To explore the effect of gabexate combined with octreotide in the treatment of patients with mild acute pancreatitis and its effect on intestinal mucosal barrier function,serum amylase(Samy)and urine amylase(Uamy)levels.Methods Totally 81 mild acute pancreatitis patients admitted to the Department of Gastroenterology of our hospital from September 10,2018 to September 10,2020 were selected as the research objects.Divided into 2 groups by a random number table.40 cases in the control group were given continuous intravenous octreotide treatment,and 41 cases in the observation group were treated with gabexate on the basis of the control group.The clinical efficacy,intestinal mucosal barrier function,biochemistry and treatment safety of the two groups were compared.Results After treatment,the total effective rate of the control group was 77.50%,which was lower than the observation group’s 97.56%,χ^(2)=7.530,P=0.006.After treatment,the endotoxin level in the control group was(4.35±1.28)EU/ml,which was higher than the observation group(3.04±0.96)EU/ml,t=5.219,P<0.001.The plasma diamine oxidase(DAO)level was(4.16±1.13)ng/L,higher than the observation group(2.84±0.55)ng/L,t=6.710,P<0.001.The D-lactic acid level was(2.87±0.31)mg/L,higher than the observation group(2.04±0.26)mg/L,t=13.069,P<0.001.The urine lactulose/mannitol(L/M)level was 0.23±0.05,higher than the observation group’s 0.13±0.03,t=10.946,P<0.001.After treatment,the Samy level in the control group was(451.02±86.70)IU/L,which was higher than the observation group(401.25±71.45)IU/L,t=2.822,P=0.006.The Uamy level was(1674.19±714.23)IU/L,higher than the observation group(1141.25±469.24)IU/L,t=3.979,P<0.001.The incidence of adverse reactions in the control group and observation group were 12.50%and 17.07%,respectively,the difference was not statistically significant,χ^(2)=0.336,P=0.562.Conclusion Gabexate combined with octreotide in mild acute pancreatitis patients can restore the intestinal mucosal barrier function,adjust the levels of

关 键 词：加贝酯 奥曲肽 急性胰腺炎 肠黏膜屏障功能 血清淀粉酶 尿淀粉酶 

分 类 号：R576[医药卫生—消化系统] R816.5[医药卫生—内科学]